CLARINEX Drug Patent Profile

Which patents cover Clarinex, and what generic alternatives are available?

Clarinex is a drug marketed by Organon Llc and Organon and is included in five NDAs.

The generic ingredient in CLARINEX is desloratadine; pseudoephedrine sulfate. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the desloratadine; pseudoephedrine sulfate profile page.

Summary for CLARINEX

US Patents:	0
Applicants:	2
NDAs:	5

Paragraph IV (Patent) Challenges for CLARINEX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
CLARINEX	Oral Solution	desloratadine	0.5 mg/mL	021300	1	2008-05-08
CLARINEX	Orally Disintegrating Tablets	desloratadine	2.5 mg and 5 mg	021165	3	2006-06-21

US Patents and Regulatory Information for CLARINEX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Organon Llc	CLARINEX	desloratadine	SOLUTION;ORAL	021300-001	Sep 1, 2004		DISCN	Yes	No
Organon	CLARINEX	desloratadine	TABLET;ORAL	021165-001	Dec 21, 2001	AB	RX	Yes	Yes
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-002	Jul 14, 2005		DISCN	Yes	No
Organon	CLARINEX	desloratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021312-001	Jun 26, 2002		DISCN	Yes	No
Organon Llc	CLARINEX-D 12 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021313-001	Feb 1, 2006		RX	Yes	Yes
Organon	CLARINEX D 24 HOUR	desloratadine; pseudoephedrine sulfate	TABLET, EXTENDED RELEASE;ORAL	021605-001	Mar 3, 2005		DISCN	Yes	No

International Patents for CLARINEX

See the table below for patents covering CLARINEX around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	4237822
Norway	20020211
Japan	S61501205
Poland	344714
Japan	3412694
Australia	570306
Hungary	T38332

Supplementary Protection Certificates for CLARINEX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1110543	SPC/GB08/005	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/005 GRANTED TO MERCK SHARP + DOHME CORP. IN RESPECT OF THE PRODUCT DESLORATADINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN COMBINATION WITH PSEUDOEPHEDRINE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6322 DATED 21 JULY 2010 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 31 JULY 2022.
1110543	08C0004	France		PRODUCT NAME: DESLORATADINE; PSEUDOEPHEDRINE SULFATE; REGISTRATION NO/DATE: EU/1/07/399/001 20070730
1110543	C 2008 001	Romania		PRODUCT NAME: COMBINATIE DE DESLORATADINA, OPTIONAL SUB FORMA DE SAREACCEPTABILA FARMACEUTIC SI PSEUDOEFEDRINA OPTIONAL SUB FORMA DE SARE SAU ESTER ACCEPTABILEFARMACEUTIC; NATIONAL AUTHORISATION NUMBER: RO EU/1/07/399/001, RO EU/1/07/399/002, RO EU/1/07/399/003, RO EU/1/07/399/004, RO EU/1/07/399/005, RO EU/1/07/399/006; DATE OF NATIONAL AUTHORISATION: 20070730; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/07/399/001, EU/1/07/399/002, EU/1/07/399/003, EU/1/07/399/004, EU/1/07/399/005, EU/1/07/399/006; DATE OF FIRST AUTHORISATION IN EEA: 20070730
0152897	SPC/GB01/012	United Kingdom		PRODUCT NAME: DESLORATADINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/00/157/001-013 20010115; UK EU/1/00/158/001-013 20010115; UK EU/1/00/159/001-013 20010115; UK EU/1/00/160/001-013 20010115; UK EU/1/00/161/001-013 20010115
0152897	2001C/013	Belgium		PRODUCT NAME: DESLORATADINE; REGISTRTION NO/DATE: EU/1/00/160/010 20010115
0152897	C00152897/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
1110543	CA 2008 00010	Denmark		PRODUCT NAME: KOMBINATION OMFATTENDE DESLORATADIN OG PSEUDOEPHEDRIN, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT IFOELGE NEDENSTAENDE GRUNDPATENT, HERUNDER PSEUDOEPHEDRIN SOM SULFAT

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for CLARINEX (Clarinex / Desloratadine)

Last updated: February 3, 2026

Summary

This report examines the investment landscape, market variables, and financial outlook for CLARINEX (desloratadine), a second-generation antihistamine indicated for allergic rhinitis and chronic idiopathic urticaria. It evaluates global demand, competitive positioning, patent landscape, regulatory environment, and revenue projections to assist stakeholders in informed decision-making.

---

1. Investment Overview and Market Demand

1.1 Product Profile

Attribute	Details
Drug Name	CLARINEX (generic: Desloratadine)
Therapeutic Class	Second-generation antihistamine
Indications	Allergic rhinitis, chronic idiopathic urticaria
Launch Year	2001
Patent Expiry	Patented until approximately 2017-2018 (varies by jurisdiction)
Formulations	Tablets, syrup, orodispersible, pediatric formulations

1.2 Commercial History

Desloratadine is a derivative of loratadine, offering enhanced potency and fewer sedative effects. Typically, it is marketed by multiple pharmaceutical firms post-patent expiry, including Sanofi (initial proprietary rights holder), Mylan, and others.

1.3 Market Drivers

• Rise in allergic conditions driven by environmental changes.
• Increasing prevalence of allergic rhinitis globally (estimated 400 million affected worldwide[1]).
• Growing awareness and diagnosis.

1.4 Emerging Markets and Geographic Segmentation

Region	Market Size (USD billion, 2023)	CAGR (2023-2028)	Drivers
North America	1.8	3.2%	High allergy prevalence, robust OTC & Rx use
Europe	1.4	2.8%	Prescriber's preference, aging population
Asia-Pacific	2.6	6.5%	Rising urbanization, allergy awareness
Latin America	0.5	4.0%	Growing healthcare access

1.5 Market Saturation & Future Demand

• Post-patent, generic versions dominate markets, leading to price competition.
• The global antihistamine market is projected to grow at a CAGR of 4.0% through 2028.
• Increased generic penetration dilutes margins but expands volume sales.

---

2. Market Dynamics Analysis

2.1 Competitive Landscape

Competitors	Key Features	Market Share (estimated)	Strategic Moves
Sanofi (original developer)	Patented until ~2018	30-35% (pre-patent expiry)	Post-expiry generics introduced
Mylan / Viatris	Generics	20-25%	Price undercutting with low-cost manufacturing
Teva	Generics	15-20%	Broad portfolio leverage
Local/Regional Players	Variations	20-30%	Local pricing & marketing strategies

Note: The entry of multiple generics post-2018 significantly eroded proprietary margins.[2]

2.2 Regulatory Impact

• Patent expiry led to widespread generic entry, sharp decline in proprietary revenues.
• Patent landscapes show numerous secondary patents, but most expired by 2018.
• Regulatory agencies (FDA, EMA) require adherence to bioequivalence, safety data, and post-market surveillance.

2.3 Pricing and Reimbursement Dynamics

Factor	Impact
Price Competition	Intense post-patent, reducing profit margins
Reimbursement Policies	Favor generics, further pressuring pricing
OTC vs. Prescription	OTC availability increases volume but limits pricing power

2.4 Innovation & Pipeline Considerations

• No recent novel formulations or new indications for CLARINEX.
• R&D shift toward next-generation antihistamines (e.g., bilastine, rupatadine) limits pipeline opportunities.
• Value accrual depends on formulations, delivery methods, or combination therapies.

---

3. Financial Trajectory and Investment Outlook

3.1 Revenue Breakdown (Post-Patent)

Revenue Stream	Approximate Contribution	Notes
Generic Sales	80%	Dominant after patent expiry
Brand (Still Marketed)	10-15%	Limited, confined to certain markets
OTC Sales	5-10%	Growing segment, especially in emerging markets
Licensing & Royalties	<5%	Minor, mostly royalties from biosimilars/related drugs

3.2 Revenue Projections (2023-2028)

Year	Projected Global Revenue (USD billion)	Assumptions
2023	1.2	Post-patent generic growth, increased OTC sales
2024	1.3	Market expansion in Asia-Pacific
2025	1.4	Entry of biosimilars, commoditization
2026	1.45	Market saturation, price erosion stabilization
2027	1.5	Mature market, steady volume sales

3.3 Cost & Margin Dynamics

Cost Component	Expected Trend	Impact
Manufacturing	Declining	Increased margins due to scale
R&D	Minimal	Focus on formulations, not new drugs
Marketing & Distribution	Stable to declining	Budget optimization in mature markets

3.4 Investment Risks and Opportunities

Risk Factors	Impact	Mitigation Strategies
Price Erosion	Margins declining	Diversify product lines, value-added formulations
Patent Litigation	Potential patent disputes	Thorough patent landscape analysis
Market Entry Barriers	Regional restrictions	Local partnerships, regulatory compliance
Competitor Innovation	Disruption potential	Monitor pipeline, innovate delivery

Opportunities	Impact	Actions
Formulation Innovation	Differentiated products	Orally disintegrating tablets, pediatric options
Geographic Expansion	High-growth regions	Strategic partnerships in APAC, LATAM
Brand Loyalty & Awareness	Post-patent brand retention	Education campaigns, measured branding

---

4. Comparative Analysis with Other Antihistamines

Attribute	CLARINEX (Desloratadine)	Loratadine	Fexofenadine	Levocetirizine
Patent Status	Expired (~2018)	Expired	Expired	Patent expired
OTC Presence	Yes	Yes	Yes	Yes
Safety Profile	Excellent	Excellent	Excellent	Excellent
Cost	Moderate	Low	Moderate	Moderate

Key Takeaways from Comparison

• All second-generation antihistamines are near-equivalent in safety and efficacy.
• Price undercutting leads to commoditization.
• Niche formulations may provide competitive edge.

---

5. Policy and Patent Landscape

Region	Patent Expiry	Standard Patent Term	Data Exclusivity	Key Patent Cases
US	~2018	20 years from filing	5-year data exclusivity	Multiple patent challenges post-expiry
EU	~2017-2018	20 years	8+2 years data exclusivity	Patent defenses in major markets
Japan	~2018	20 years	6 years market exclusivity	Patent landscape barriers

Implications

• Post-2018, substantial generic entry.
• Strategic patent filings during early development phases can provide market exclusivity advantages in certain jurisdictions.

---

6. Conclusion and Strategic Recommendations

Conclusion	Implication	Recommended Actions
Post-patent, generic competition dominates	Revenue margins compress	Diversify into formulations, new delivery methods
Market growth driven by emerging regions	Expansion opportunities	Local partnerships, tailored marketing
Innovation pipeline limited	Focus on formulation innovation	Invest in pediatric, OTC, and combination products
Competitive pressures require differentiation	Maintain brand presence	Focus on value-added features and patient adherence

---

Key Takeaways

• CLARINEX, initially a premium branded antihistamine, now operates primarily in a commoditized, generic market segment.
• The landscape is characterized by intense price competition, a mature patent environment, and expanding emerging markets.
• Revenue growth is projected to be modest, with a CAGR of approximately 3-4% through 2028.
• Strategic innovation, formulation differentiation, and geographic diversification offer the best avenues for maintaining or increasing profitability.
• Regulatory vigilance is critical; patent expirations and litigation risks remain significant.
• Stakeholders should align their investment horizon with the maturation of generic markets, emphasizing cost efficiencies and niche formulations.

---

FAQs

Q1: What is the current patent status of CLARINEX, and how does it affect market entry?
A1: The primary patents for CLARINEX expired around 2017-2018 in major jurisdictions, leading to widespread generic entry. This has resulted in significant price competition and commoditization, reducing profit margins for proprietary formulations.

Q2: Which markets offer the most growth potential for CLARINEX?
A2: Emerging markets within Asia-Pacific and Latin America are projected to exhibit the highest CAGR (6-6.5%) driven by rising allergy prevalence and increasing healthcare access.

Q3: How does the competitive landscape impact investment decisions?
A3: The saturated generic market exerts downward pressure on margins. Differentiation via formulations, niche markets, or new indications can help sustain revenues.

Q4: Are there opportunities for innovation in CLARINEX formulations?
A4: Yes. Pediatric-friendly, orally disintegrating, or combination formulations could command higher margins and increased adherence.

Q5: What are the primary regulatory considerations post-patent expiry?
A5: Ensuring bioequivalence for generics, managing patent challenges, and adhering to safety surveillance are essential. Patent landscapes and data exclusivity periods influence the timing and scope of product launches.

---

References

[1] Alper, S. "Global Allergy and Asthma Market Outlook," MarketResearch.com, 2022.
[2] IMS Health. "Impact of Patent Expiry on Antihistamine Markets," 2021.